FDA has approved dipeptidyl peptidase-4 (DPP-IV) resistant long-acting GLP-1s as injectable drugs for treating patients with type 2 diabetes
Most prior incretin-family peptides act on one or two of these receptors: Semaglutide (single agonist): GLP-1 receptor only Tirzepatide (dual agonist): GLP-1 + GIP receptors Retatrutide / GLP-3RT (triple agonist): GLP-1 + GIP + glucagon receptors That third receptor glucagon is the key reason researchers describe GLP-3RT as a next-generation tool in incretin pharmacology research
Board of Pharmacy rules finalized October 2025 redefine "essentially a copy" and impose an affirmative duty on pharmacists to document patient-specific "clinically significant differences." Out-of-state pharmacies must be licensed with the California Board of Pharmacy before shipping to California patients
Jeong M, Kim HM, Kim HJ, Choi JH, Jang DS
A dose-dependent response has been observed with half (125 mg), normal (250 mg), and double (500 mg) doses, with higher doses producing greater blood sugar blunting effects
